Business Description
Bio-Rad Laboratories Inc
NAICS : 334516
SIC : 3826
ISIN : US0905722072
Share Class Description:
BIO: Class ADescription
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.25 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | 244.56 | |||||
| Interest Coverage | 7.25 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.04 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| 3-Year FCF Growth Rate | -39 | |||||
| 3-Year Book Growth Rate | 19.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.04 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.74 | |||||
| 9-Day RSI | 54.06 | |||||
| 14-Day RSI | 49.15 | |||||
| 6-1 Month Momentum % | -25.27 | |||||
| 12-1 Month Momentum % | -33.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.64 | |||||
| Quick Ratio | 4.25 | |||||
| Cash Ratio | 3.15 | |||||
| Days Inventory | 214.52 | |||||
| Days Sales Outstanding | 63.71 | |||||
| Days Payable | 40.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | -2.78 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.58 | |||||
| Operating Margin % | 13 | |||||
| Net Margin % | -5.86 | |||||
| FCF Margin % | 8.2 | |||||
| ROE % | -1.78 | |||||
| ROA % | -1.26 | |||||
| ROIC % | 2.88 | |||||
| ROC (Joel Greenblatt) % | -9.12 | |||||
| ROCE % | -1.15 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 23.09 | |||||
| PE Ratio without NRI | 26.99 | |||||
| Shiller PE Ratio | 12.44 | |||||
| PS Ratio | 3.33 | |||||
| PB Ratio | 1.06 | |||||
| Price-to-Tangible-Book | 1.16 | |||||
| Price-to-Free-Cash-Flow | 40.61 | |||||
| Price-to-Operating-Cash-Flow | 24.24 | |||||
| EV-to-EBIT | -62.07 | |||||
| EV-to-Forward-EBIT | 19.4 | |||||
| EV-to-EBITDA | 1495.28 | |||||
| EV-to-Forward-EBITDA | 15.08 | |||||
| EV-to-Revenue | 3.16 | |||||
| EV-to-Forward-Revenue | 3.04 | |||||
| EV-to-FCF | 38.54 | |||||
| Price-to-Projected-FCF | 0.94 | |||||
| Price-to-Median-PS-Value | 0.87 | |||||
| Price-to-Graham-Number | 1.18 | |||||
| Earnings Yield (Greenblatt) % | -1.61 | |||||
| FCF Yield % | 2.49 | |||||
| Forward Rate of Return (Yacktman) % | 23.22 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:BIO
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bio-Rad Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,720.366 | ||
| EPS (TTM) ($) | -5.85 | ||
| Beta | 0.95 | ||
| Volatility % | 36.63 | ||
| 14-Day RSI | 49.15 | ||
| 14-Day ATR ($) | 8.739486 | ||
| 20-Day SMA ($) | 303.861 | ||
| 12-1 Month Momentum % | -33.62 | ||
| 52-Week Range ($) | 261.59 - 509.6225 | ||
| Shares Outstanding (Mil) | 29.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bio-Rad Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bio-Rad Laboratories Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bio-Rad Laboratories Inc Frequently Asked Questions
What is Bio-Rad Laboratories Inc(BIO)'s stock price today?
The current price of BIO is $307.00. The 52 week high of BIO is $509.62 and 52 week low is $261.59.
When is next earnings date of Bio-Rad Laboratories Inc(BIO)?
The next earnings date of Bio-Rad Laboratories Inc(BIO) is 2024-02-16 Est..
Does Bio-Rad Laboratories Inc(BIO) pay dividends? If so, how much?
Bio-Rad Laboratories Inc(BIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers